Anocca

Anocca is a pioneering precision T cell immunotherapy company focused on developing innovative treatments for untreatable cancers. The company operates in the biotechnology sector, primarily serving healthcare providers and patients in need of advanced cancer therapies. Anocca's core business model revolves around engineering T cell receptor (TCR) T cell therapies, which harness the natural ability of T cells to recognize and target disease markers within cancer cells. This approach opens up a largely unexplored source of therapeutic targets, offering new hope for precision cancer treatments.

Founded in 2014, Anocca has built a robust infrastructure and biotechnologies to decode T cell immunity. Over the past decade, the company has developed a deep tech platform to analyze T cell biology at scale. This platform supports the development and manufacturing of TCR T cell therapy libraries, specifically designed for the hardest-to-treat cancers.

Anocca's team comprises over 100 scientists, software developers, engineers, manufacturing and quality specialists, and dedicated support and business personnel. The company operates out of state-of-the-art facilities in Sweden, leveraging a multicultural and multidisciplinary team from over 35 nations. This diverse talent pool is considered one of Anocca's key strengths.

Revenue is generated through the development and commercialization of TCR T cell therapies, with a focus on delivering high-quality cell therapy products. The company's next-generation gene editing system enhances the precision and efficiency needed to scale its manufacturing processes.

Keywords: T cell immunotherapy, TCR T cell therapy, precision cancer treatment, biotechnology, gene editing, healthcare, deep tech platform, cancer therapy, Sweden, multidisciplinary team.